Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001714899-26-000056
Filing Date
2026-04-21
Accepted
2026-04-21 16:34:15
Documents
3

Document Format Files

Seq Description Document Type Size
1 DEFA14A ADDITIONAL MATERIALS a2026fy25defa14aproxy-defi.htm DEFA14A 10531
2 denalitherapeuticsinc_vxna.jpg GRAPHIC 498143
3 denalitherapeuticsinc_vxnaa.jpg GRAPHIC 300786
  Complete submission text file 0001714899-26-000056.txt   1111526
Mailing Address 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080
Business Address 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080 (650) 866-8547
Denali Therapeutics Inc. (Filer) CIK: 0001714899 (see all company filings)

EIN.: 463872213 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-38311 | Film No.: 26880003
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)